OpportunityTitle: Multimorbidity in Alzheimers Disease Impacts Choice of Ancillary Treatments (R21/R33)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description: This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and related dementia (ADRD). Studies may be observational treatment studies or pragmatic clinical trials. This FOA will support pilot research to test the feasibility of interventions (R21 phase) that, if successful, can transition to an R33 phase for implementation of pragmatic trials. The transition from the R21 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the criteria that are specified in the R21 phase.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;